Vascular Graft Market by Raw Material, Product, Application, End-User

List of Tables

[189 Pages Report] The Vascular Graft Market size was estimated at USD 3.51 billion in 2023 and expected to reach USD 3.77 billion in 2024, at a CAGR 7.39% to reach USD 5.79 billion by 2030.

A vascular graft is a surgical process that redirects blood flow around a blocked or partially blocked artery in the heart by using a blood vessel taken from another part of your body, also known as a graft. Vascular grafts can be made from various materials, including synthetic polymers, such as polytetrafluoroethylene (PTFE) and polyurethane, and biological materials, such as collagen and human or animal tissue. The rise in the prevalence of vascular disorders and the rise in the geriatric population prone to cardiovascular diseases increases the adoption of vascular grafts. However, the risk of complications post-implantation of a vascular graft, such as graft infection and blood clots, may further hinder the adoption of the vascular graft. Nevertheless, the rise of biomaterial research for developing advanced, biocompatible grafts and the ongoing advancements in vascular imaging technologies such as 3D angiography offer potential for significant growth opportunities for the market.

KEY MARKET STATISTICS
Base Year [2023]	USD 3.51 billion
Estimated Year [2024]	USD 3.77 billion
Forecast Year [2030]	USD 5.79 billion
CAGR (%)	7.39%

Raw Material: Burgeoning utilization of polytetrafluoroethylene-based vascular grafts owing to their biocompatibility and flexibility

The vascular grafts made from biological materials, including human saphenous and umbilical veins, are used widely due to their inherent compatibility and decreased chances of rejection in the human body. They display moderate compliance, excellent long-term patency, and minimal antigenicity. These materials are preferred for vascular grafts that require a smaller diameter, such as lower extremity bypass procedures or coronary artery bypass grafting. Tissue-engineered materials are engineered to mimic the natural body tissue and have the advantage of being biocompatible and biodegradable. The goal of tissue-engineered grafts is to provide a living, autologous construct that could grow with the patient, remodel, and repair itself while reducing the risk of graft failure, infection, and rejection. Polyester grafts exhibit enhanced tensile strength; they tend to be less compliant than natural blood vessels. PTFE, on the other hand, while not as durable as polyester, presents high hemocompatibility and is more commonly used due to its flexibility and superior biocompatibility. Polyurethane is a useful material due to its tunable properties, including variable hardness, flexibility, elasticity, and biostability.

Product: Proliferating usage of peripheral vascular graft for restoring blood flow in patients with blockages in the peripheral arteries

Coronary Artery Bypass Graft (CABG) is a surgically created connection between the coronary artery and aorta or larger veins that enables blood flow to bypass blockage in the heart. CABG is generally preferred when the patient has multiple artery diseases, left main coronary artery disease, or severe symptoms of coronary artery disease. An endovascular stent graft is a tube comprised of fabric supported by a metal mesh used to treat ailments such as abdominal aortic aneurysms. The patient population with a high surgical risk or refusal of open surgery prefers this. Hemodialysis access grafts are surgically implanted to provide a durable and reliable access point for hemodialysis treatments in patients with chronic kidney disease. They are preferred when patients' vessels are not suitable for creating arteriovenous (AV) fistula. Peripheral vascular grafts help restore blood flow to the parts of the body other than the brain and the heart. Used primarily in cases of peripheral artery disease, these grafts prove beneficial for patients with blockages in the peripheral arteries.

Application: Significant use of vascular grafts in treating cardiovascular diseases

Aneurysms, defined as abnormal extensions or bulges in blood vessel walls, often require intervention through vascular grafts. These grafts, utilizing synthetic materials or autogenous tissue, are used to bypass the aneurysmal site, helping to prevent rupture and subsequent serious consequences. New developments in the field have led to the creation of endovascular stent grafts for treating abdominal and thoracic aortic aneurysms, offering a less invasive alternative to traditional open surgery. Cardiovascular disease is another area where vascular grafts have a pivotal role. Coronary artery disease, peripheral artery disease, and massive myocardial infarction necessitate the use of these grafts. Surgeons utilize them for procedures such as coronary artery bypass grafting (CABG) and peripheral bypass procedures, restoring blood flow to ischemic areas, subsequently reducing cardiac morbidity and mortality. Diabetes often leads to peripheral vascular disease characterized by occlusive and stenotic lesions in the peripheral arteries. Vascular grafts, including autologous veins and synthetic materials, are used for bypassing these occluded sections, helping restore perfusion and reducing the risk of limb amputations. Renal or kidney failure, specifically end-stage renal disease (ESRD), requires life-saving hemodialysis. This process mandates reliable vascular access, achieved through the creation of arteriovenous fistulae (AVF) or grafts (AVG) for continuous dialysis access. Vascular occlusion, relating to blockage or closure of blood vessels, is a common condition necessitating the use of vascular grafts. Vascular grafts serve as conduits to restore blood flow, able to withstand the body's natural hemodynamic forces. Intraluminal stent grafts or bypass grafts, comprising biological, biocompatible, or synthetic materials, are often employed depending on the location and extent of occlusion.

End-User: Significant applications of vascular grafts in ambulatory surgical centers (ASCs)

Ambulatory Surgical Centers (ASCs) commonly perform procedures such as bypass surgery or placing stents, which often require the implantation of vascular grafts. The ASGs are witnessing a surge in vascular graft usage due to their focus on providing cost-effective, high-quality care that results in improved recovery and better patient satisfaction. Hospital-based procedures requiring vascular grafts remain high, with a constantly growing need due to complex surgeries being performed. Grafts deployed in the hospital setting often need to serve diverse surgical requirements, necessitating a broad portfolio of options. Hospitals have been traditionally more centered on complicated surgeries requiring vascular grafts. However, the rise in minimally invasive procedures and the trend towards cost-saving is shifting preferences towards ASCs.

Regional Insights

The vascular graft market is evolving in the Americas owing to technological advancements, rising healthcare expenditure, and the prevalence of cardiovascular disorders and diabetes in the region. Strong focus on regulatory compliance and safety measures, substantial research and development projects, increasing awareness regarding vascular grafts, and growing healthcare infrastructure encourage using vascular graft procedures to improve treatment outcomes in the EMEA region. Growing prevalence of lifestyle diseases and the accelerating expansion of healthcare services, significant medical technology advancements are resulting in the development of enhanced vascular graft procedures in the APAC region. Besides, the development of bioengineered vascular grafts that mimic the natural blood vessel structure and composition is anticipated to increase the use of this medical procedure by health professionals to treat various medical conditions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vascular Graft Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vascular Graft Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vascular Graft Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Affluent Medical, B. Braun Melsungen AG, Becton, Dickinson and Company, BIOVIC Sdn. Bhd., Boston Scientific Corporation, Cardinal Health Inc., Cook Medical, Inc., Corcym S.r.l., CryoLife, Inc., Endologix Inc., Getinge AB, Heart Medical Europe B.V., Japan Lifeline Co., Ltd., Lemaitre Vascular, Inc., Medtronic PLC, Merit Medical Systems, Inc., Perouse Medical SAS by Vygon SAS, Rua Life Sciences PLC, Shanghai Suokang Medical Implants Co. Ltd., Terumo Corporation, Vascular Graft Solutions Ltd., VUP Medical, W. L. Gore & Associates, Inc., and Xeltis B.V..

Market Segmentation & Coverage

This research report categorizes the Vascular Graft Market to forecast the revenues and analyze trends in each of the following sub-markets:

Raw Material
- Biological Materials
  - Human Saphenous & Umbilical Veins
  - Tissue Engineered Materials

Polyester
Polytetrafluoroethylene
Polyurethane

Product
- Coronary Artery By-Pass Graft
- Endovascular Stent Graft
- Hemodialysis Access Graft
- Peripheral Vascular Graft

Application
- Aneurysm
- Cardiovascular
- Diabetes
- Kidney Failure
- Vascular Occlusion

End-User
- Ambulatory Surgical Center
- Hospital

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vascular Graft Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vascular Graft Market?

3. What are the technology trends and regulatory frameworks in the Vascular Graft Market?

4. What is the market share of the leading vendors in the Vascular Graft Market?

5. Which modes and strategic moves are suitable for entering the Vascular Graft Market?

Product Code: MRR-034B50030374

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of lifestyle-related disorders globally
  - 5.1.1.2. Growing preference for minimally invasive procedures
  - 5.1.1.3. Rising number of clinical trials of vascular grafts
- 5.1.2. Restraints
  - 5.1.2.1. High treatment cost of vascular graft procedures
- 5.1.3. Opportunities
  - 5.1.3.1. Improvements in the design and performance of vascular grafts
  - 5.1.3.2. Development of tissue-engineered vascular grafts
- 5.1.4. Challenges
  - 5.1.4.1. Infections associated with vascular grafts
5.2. Market Segmentation Analysis
- 5.2.1. Raw Material: Burgeoning utilization of polytetrafluoroethylene-based vascular grafts owing to their biocompatibility and flexibility
- 5.2.2. Product: Proliferating usage of peripheral vascular graft for restoring blood flow in patients with blockages in the peripheral arteries
- 5.2.3. Application: Significant use of vascular grafts in treating cardiovascular diseases
- 5.2.4. End-User: Significant applications of vascular grafts in ambulatory surgical centers (ASCs)
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Vascular Graft Market, by Raw Material

6.1. Introduction
6.2. Biological Materials
6.3. Polyester
6.4. Polytetrafluoroethylene
6.5. Polyurethane

7. Vascular Graft Market, by Product

7.1. Introduction
7.2. Coronary Artery By-Pass Graft
7.3. Endovascular Stent Graft
7.4. Hemodialysis Access Graft
7.5. Peripheral Vascular Graft

8. Vascular Graft Market, by Application

8.1. Introduction
8.2. Aneurysm
8.3. Cardiovascular
8.4. Diabetes
8.5. Kidney Failure
8.6. Vascular Occlusion

9. Vascular Graft Market, by End-User

9.1. Introduction
9.2. Ambulatory Surgical Center
9.3. Hospital

10. Americas Vascular Graft Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Vascular Graft Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Vascular Graft Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Aquedeon Medical, Inc. Receives FDA IDE Approval for the Duett Vascular Graft System
- 13.3.2. Xeltis' aXess Vascular Graft Development Receives Funding From European Innovation Council
- 13.3.3. Vygon Partners with Carmat to Develop a Vascular Graft for an Artificial Heart
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio